SCHEMBL4867665

SCHEMBL4867665

COc1ccc(CNc2nc(C(OC)c3ccccc3)nc3ccccc23)cc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
APP P05067 4/20 0.64
SLC2A1 P11166 1/20 0.57
EGFR P00533 3/20 0.57
POLB P06746 2/20 0.57
NR2F2 P24468 1/20 0.57
USP1 O94782 1/20 0.54
WDR48 Q8TAF3 1/20 0.54
LMNA P02545 4/20 0.53
TP53 P04637 1/20 0.53
CYP1A2 P05177 2/20 0.51
CYP3A4 P08684 2/20 0.51
CYP2D6 P10635 2/20 0.51
TSHR P16473 2/20 0.51
MAPK1 P28482 2/20 0.51
CYP2C19 P33261 2/20 0.51
HSD17B10 Q99714 2/20 0.51
NCF1 P14598 1/20 0.51
USP2 O75604 1/20 0.51
ALDH1A1 P00352 1/20 0.51
CYP2C9 P11712 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4930371 0.90 APP (0.54) APPSLC2A1EGFRPOLBNR2F2
SCHEMBL4860039 0.88 APP (0.66) APPSLC2A1EGFRLMNATP53
SCHEMBL5104358 0.87 APP (0.65) APPSLC2A1EGFRPOLBNR2F2
SCHEMBL4868260 0.86 APP (0.70) APPSLC2A1EGFRPOLBNR2F2
SCHEMBL4864516 0.86 APP (0.66) APPCYP1A2CYP3A4MEN1KMT2A
SCHEMBL5102203 0.84 CYP1A2 (0.64) LMNATP53CYP1A2CYP3A4CYP2D6
SCHEMBL5100498 0.84 CYP1A2 (0.53) APPLMNATP53CYP1A2CYP3A4
SCHEMBL4866281 0.84 APP (0.52) APPLMNACYP1A2CYP3A4CYP2D6
SCHEMBL4863914 0.84 CYP1A2 (0.48) APPLMNATP53CYP1A2CYP3A4
SCHEMBL4864380 0.82 CYP1A2 (0.61) SLC2A1LMNATP53CYP1A2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080207614-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY SK CHEMICALS CO., LTD. (KR) 2008-08-28 US claimed
JP-2008526734-A 2008-07-24 JP claimed
EP-1844023-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY SK CHEMICALS CO., LTD. (KR) 2007-10-17 EP claimed
WO-2006071095-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY SK CHEMICALS CO., LTD. (KR) 2006-07-06 WO claimed
US-20080207614-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY SK CHEMICALS CO., LTD. (KR) 2008-08-28 US disclosed
EP-1844023-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY SK CHEMICALS CO., LTD. (KR) 2007-10-17 EP disclosed
WO-2006071095-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY SK CHEMICALS CO., LTD. (KR) 2006-07-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080207614-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY GPR119, GCKR, GLP1R APP 4386/4885SLC2A1 21/4885EGFR 4822/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.